Rein Therapeutics, Inc. Business Acquisition, Pro Forma Revenue
Rein Therapeutics, Inc. (RNTX) reported Business Acquisition, Pro Forma Revenue of $153.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-04-15.
Discontinued › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2024-04-15
- Rein Therapeutics, Inc. business acquisition, pro forma revenue for fiscal 2023 was $153.00K, a 77.76% decline from fiscal 2022.
- Rein Therapeutics, Inc. business acquisition, pro forma revenue for fiscal 2022 was $688.00K.
| Period end | Business Acquisition, Pro Forma Revenue 12 month |
|---|---|
| 2023-12-31 | $153.00K 10-K · filed 2024-04-15 |
| 2022-12-31 | $688.00K 10-K · filed 2024-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |